Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299501 | 0.86 | — | — | |
| SCHEMBL733409 | 0.85 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL12568390 | 0.80 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL11237347 | 0.80 | — | — | |
| SCHEMBL17943797 | 0.80 | CYP3A4 (0.48) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL7006853 | 0.80 | TSHR (0.56) | CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL15977306 | 0.80 | TSHR (0.56) | CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL18291794 | 0.78 | BTN3A1 (0.32) | — | |
| SCHEMBL18250798 | 0.78 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL29285238 | 0.77 | ALDH1A1 (0.32) | CYP3A4ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322843-A1 | Process for the preparation of oligonucleotides using modified oxidation protocol | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322843-A1 | Process for the preparation of oligonucleotides using modified oxidation protocol | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230295207-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2022008594-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | F. HOFFMANN-LA ROCHE AG (CH) | 2022-01-13 | — | — | WO | disclosed |
| WO-2020249571-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| US-8450440-B2 | Method for purifying polymer and polymer | MITSUI CHEMICALS, INC. (JP) | 2013-05-28 | — | — | US | disclosed |
| WO-2013009735-A1 | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20120208976-A1 | METHOD FOR PURIFYING POLYMER AND POLYMER | MITSUI CHEMICALS, INC (JP) | 2012-08-16 | — | — | US | disclosed |
| US-7820391-B2 | having relatively high coupling efficiency that are particularly useful in nucleic acid synthesis; has a redox active moiety comprising a ferrocene derivative; non-nucleotide ferrocene labels; kits | OSMETECH MOLECULAR DIAGNOSTICS (US) | 2010-10-26 | — | — | US | disclosed |
| US-7812180-B2 | Electropolymerisable monomers that are soluble in aqueous solution and electroactive probes that can be obtained with such monomers | BIOMERIEUX (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20090155795-A1 | BASELESS NUCLEOTIDE ANALOGUES AND USES THEREOF | OSMETECH MOLECULAR DIAGNOSTICS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090053826-A1 | Electropolymerisable monomers that are soluble in aqueous solution and electroactive probes that can be obtained with such monomers | BIOMERIEUX (FR) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295207-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES USING MODIFIED OXIDATION PROTOCOL | POLN, POLRMT, POLR2E | CYP3A4 2325/4885ALDH1A1 2274/4885TDP1 356/4885 |
| US-20230322843-A1 | Process for the preparation of oligonucleotides using modified oxidation protocol | POLRMT, POLB, POLM | CYP3A4 1361/4885ALDH1A1 1882/4885TDP1 642/4885 |
| US-20090155795-A1 | BASELESS NUCLEOTIDE ANALOGUES AND USES THEREOF | RNGTT, NTPCR, RNMT | CYP3A4 4349/4885ALDH1A1 3782/4885TDP1 328/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | CYP3A4 3034/4885ALDH1A1 3610/4885TDP1 765/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | CYP3A4 3034/4885ALDH1A1 3610/4885TDP1 765/4885 |
| US-20090053826-A1 | Electropolymerisable monomers that are soluble in aqueous solution and electroactive probes that can be obtained with such monomers | CD14, SELE, ENTPD1 | CYP3A4 1877/4885ALDH1A1 345/4885TDP1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.